HFCAS OpenIR

浏览/检索结果: 共3条,第1-3条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 139, 期号: 无, 页码: 674-697
作者:  Chen, Yongfei;  Wu, Jiaxin;  Wang, Aoli;  Qi, Ziping;  Jiang, Taoshan;  Chen, Cheng;  Zou, Fengming;  Hu, Chen;  Wang, Wei;  Wu, Hong;  Hu, Zhenquan;  Wang, Wenchao;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Liu, Qingsong;  Liu, Jing
浏览  |  Adobe PDF(12656Kb)  |  收藏  |  浏览/下载:21282/11467  |  提交时间:2018/08/17
Egfr  Alk  Dual Kinase Inhibitor  Non-small Cell Lung Cancer  
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏  |  浏览/下载:33/0  |  提交时间:2020/10/26
EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy  
Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice 期刊论文
ACTA PHARMACOLOGICA SINICA, 2017, 卷号: 38
-
收藏  |  浏览/下载:30/0  |  提交时间:2020/10/26
BRAIN METASTASES  CEREBROSPINAL-FLUID  GEFITINIB  INHIBITORS  CARCINOMA  RADIATION  ERLOTINIB  afatinib  tyrosine kinase inhibitor  non-small cell lung cancer  brain metastasis  pharmacokinetic/pharmacodynamics  pEGFR